OtherClinical Investigations (Human)
Safety, Pharmacokinetics and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analogue 177Lu-DOTA-EB-TATE in Patients with Advanced Metastatic Neuroendocrine Tumors
Jingjing Zhang, Hao Wang, Orit Jacobson Weiss, Yuejuan Cheng, Gang Niu, Fang Li, Chunmei Bai, Zhaohui Zhu and Xiaoyuan Chen
Journal of Nuclear Medicine April 2018, jnumed.118.209841; DOI: https://doi.org/10.2967/jnumed.118.209841
Jingjing Zhang
1 Peking Union Medical College Hospital (PUMCH), China;
Hao Wang
1 Peking Union Medical College Hospital (PUMCH), China;
Orit Jacobson Weiss
2 National Institutes of Health, United States;
Yuejuan Cheng
1 Peking Union Medical College Hospital (PUMCH), China;
Gang Niu
2 National Institutes of Health, United States;
Fang Li
3 Peking Union Medical College Hospital, China
Chunmei Bai
1 Peking Union Medical College Hospital (PUMCH), China;
Zhaohui Zhu
1 Peking Union Medical College Hospital (PUMCH), China;
Xiaoyuan Chen
2 National Institutes of Health, United States;
Article Figures & Data
Additional Files
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 65, Issue 4
April 1, 2024
Safety, Pharmacokinetics and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analogue 177Lu-DOTA-EB-TATE in Patients with Advanced Metastatic Neuroendocrine Tumors
Jingjing Zhang, Hao Wang, Orit Jacobson Weiss, Yuejuan Cheng, Gang Niu, Fang Li, Chunmei Bai, Zhaohui Zhu, Xiaoyuan Chen
Journal of Nuclear Medicine Apr 2018, jnumed.118.209841; DOI: 10.2967/jnumed.118.209841
Safety, Pharmacokinetics and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analogue 177Lu-DOTA-EB-TATE in Patients with Advanced Metastatic Neuroendocrine Tumors
Jingjing Zhang, Hao Wang, Orit Jacobson Weiss, Yuejuan Cheng, Gang Niu, Fang Li, Chunmei Bai, Zhaohui Zhu, Xiaoyuan Chen
Journal of Nuclear Medicine Apr 2018, jnumed.118.209841; DOI: 10.2967/jnumed.118.209841
Jump to section
Related Articles
Cited By...
- Efficacy of [67Cu]Cu-EB-TATE Theranostic Against Somatostatin Receptor Subtype-2-Positive Neuroendocrine Tumors
- A Single-Arm, Low-Dose, Prospective Study of 177Lu-EB-PSMA Radioligand Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer
- Combined Targeted Radiopharmaceutical Therapy and Immune Checkpoint Blockade: From Preclinical Advances to the Clinic
- Albumin Binder-Conjugated Fibroblast Activation Protein Inhibitor Radiopharmaceuticals for Cancer Therapy
- Peptide Receptor Radionuclide Therapy of Late-Stage Neuroendocrine Tumor Patients with Multiple Cycles of 177Lu-DOTA-EB-TATE
- 177Lu-DOTA-EB-TATE, a Radiolabeled Analogue of Somatostatin Receptor Type 2, for the Imaging and Treatment of Thyroid Cancer
- Different Radionuclides in DOTA-EB-TATE Effect Different Uptake in Somatostatin Receptor-Positive HEK293 Cells
- Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients
- Reply: Different Radionuclides in DOTA-EB-TATE Effect Different Uptake in Somatostatin Receptor-Positive HEK293 Cells
- New Developments in Peptide Receptor Radionuclide Therapy